ABL1 and ovarian cancer: We found that ABL1 inhibitors, such as imatinib and dasatinib, exhibited a negative correlation with platinum resistance, suggesting they could serve as potential treatment options for ovarian cancer cells with overexpressed SYCP2 (Fig. 1D).